QTRXQTRXHealthcare · Medical Devices

QTRX Stock Forecast: Quanterix Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.96
−3.45% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 53 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$96.4M
Ticker Nerd rank
53/ 100
Median analyst target
$3.00
Analysts covering
—
Revenue$32.9M+34.6% y/y
Operating income−$22.5M
Net income−$48.9M
Free cash flow−$5.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−33.1%
1M
−27.9%
YTD
−69.2%
1Y
−66.8%
From 52W high
−75.7%
From 52W low
0.0%
$1.96
$8.06
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Quanterix Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
53/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
92
Accruals
87
Issuance
70
Quality
40
Volatility
38
Value
35
Revisions
29
Momentum
16

Growth (92): Sales and profits are climbing, and climbing faster than before.

Momentum (16): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

QTRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on QTRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00$6.00$7.00$8.00Jan 26Apr 26Jul 26Oct 26QTRXHigh $4.00Median $3.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
10 Nov 2026TD CowenMaintainsHold$3.50 → $4.00
13 Oct 2026TD CowenMaintainsHold$3.00 → $3.50
17 Aug 2026Canaccord GenuityMaintainsHold$4.00 → $3.00
11 Aug 2026TD CowenMaintainsHold$4.00 → $3.00
7 May 2026TD CowenMaintainsHold$7.00 → $4.00
20 Apr 2026Canaccord GenuityMaintainsHold—
22 Dec 2025Canaccord GenuityMaintainsHold—
11 Aug 2025Canaccord GenuityDowngradeHold—
13 May 2025Canaccord GenuityMaintainsBuy—
30 Apr 2025Leerink PartnersDowngradeMarket Perform—
25 Mar 2025ScotiabankMaintainsSector Outperform—
18 Mar 2025Canaccord GenuityMaintainsBuy—
13 Nov 2024TD CowenMaintainsHold—
12 Aug 2024ScotiabankMaintainsSector Outperform—
9 Aug 2024TD CowenMaintainsHold—
9 July 2024Goldman SachsMaintainsBuy—
29 Apr 2024Canaccord GenuityMaintainsBuy—
4 Mar 2024ScotiabankMaintainsSector Outperform—
28 Sept 2023Goldman SachsMaintainsBuy—
27 Sept 2023Goldman SachsMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

QTRX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

QTRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Quanterix Corp. returned −66.8% against +6.9% for the S&P 500, dividends included.

QTRX vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Jan 26Apr 26Jul 26Oct 26QTRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

QTRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.6×

Cheaper than 76% of US stocks

Price / book
0.4×

Cheaper than 88% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
38.5%

Higher than 47% of US stocks

Operating margin
−53.6%

Higher than 18% of US stocks

Net margin
—
Returns & dividend
Return on equity
−41.7%

Higher than 24% of US stocks

Return on assets
−13.3%

Higher than 24% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Quanterix Corp. has a market value of $96.4M and an enterprise value of $50.4M.

  • Revenue in the twelve months to 30 June 2026: $153.2M. The latest quarter grew 34.6% year on year.

  • Net income over the same four quarters: −$123.1M, a −80.3% net margin.

  • Diluted earnings per share, trailing twelve months: −$2.63.

  • Free cash flow in the twelve months to 30 June 2026: −$81.7M.

  • Shares outstanding: 47.1M.

  • Quanterix Corp. employs 450 people — $341K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

QTRX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
QTRXQuanterix Corp.$96.4M53
CATXPerspective Therapeutics, Inc.$91.0M11
STIMNeuronetics, Inc.$95.2M64
OWLTOwlet, Inc.$85.0M27
APYXApyx Medical Corp.$101.1M76
LUNGPulmonx Corp.$111.9M87
LUCDLucid Diagnostics, Inc.$75.7M36

Take a look at QTRX’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Quanterix Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about QTRX

How does Ticker Nerd's model rank QTRX?

As at 21 Nov 2026, Quanterix Corp. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).

What is the QTRX stock forecast for 2030?

No analyst covering Quanterix Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QTRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $4 over the next 12 months.

How has QTRX stock performed over the past year?

Quanterix Corp. returned -66.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Quanterix Corp. do?

Quanterix Corporation is a life sciences tools and diagnostics company that develops ultra-sensitive digital immunoassay platforms for research and clinical applications. Quanterix’s core products and services include the Simoa assay kits, automated analyzers, biomarker detection systems, imaging and analysis platforms, and laboratory services used to measure very low levels of proteins and other biomarkers in blood and related fluids.

Company

About Quanterix Corp.

Quanterix Corporation is a life sciences tools and diagnostics company that develops ultra-sensitive digital immunoassay platforms for research and clinical applications. Quanterix’s core products and services include the Simoa assay kits, automated analyzers, biomarker detection systems, imaging and analysis platforms, and laboratory services used to measure very low levels of proteins and other biomarkers in blood and related fluids. The company supports work across disease research, diagnostics, and drug development, helping laboratories and healthcare organizations generate precise biomarker data for scientific and clinical use. Quanterix serves customers in North America, Europe, the Middle East, Africa, and the Asia Pacific regions, with offerings used by academic researchers, biopharmaceutical companies, and clinical laboratories. Founded in 2007 and headquartered in Billerica, Massachusetts, Quanterix Corporation plays a specialized role in precision biomarker science and advanced diagnostic testing.

CEO Mr. Everett V. Cunningham · 450 employees · United States · https://www.quanterix.com